Sudden Drop in Pump Flow May Signal Early HeartMate 3 Clot Formation

When a mechanical heart pump begins to fail, the earliest warning signs are not always the ones clinicians have been trained to watch. A new case report from Kurume University School of Medicine in Japan suggests that an abrupt, unexplained decline in pump flow may be the first and most important signal of thrombosis in the HeartMate 3 left ventricular assist device, even when the blood tests that traditionally define pump thrombosis remain nearly normal. The finding, published in the Journal of Artificial Organs, challenges the reliance on hemolysis markers as the primary trigger for urgent investigation and adds a new dimension to the surveillance of patients supported by one of the world’s most widely implanted heart pumps.

The report centers on a man in his fifties who developed pump thrombosis just fourteen days after receiving a HeartMate 3 implant. The HeartMate 3, manufactured by Abbott, is a fully magnetically levitated centrifugal-flow pump designed to minimize blood trauma. Its artificial pulse feature and wide blood-flow gaps were engineered specifically to reduce the risk of thrombosis, and large randomized trials have indeed shown remarkably low rates of pump thrombosis compared with older axial-flow devices. That very success, however, means that when thrombosis does occur, clinicians may have little experience recognizing it, particularly in the early postoperative period when it is rarest and hardest to diagnose.

In this case, the patient’s initial presentation was strikingly subtle. He remained clinically stable, with no overt signs of heart failure, device malfunction, or systemic illness. Laboratory abnormalities were present but mild, lacking the dramatic elevations in plasma free hemoglobin and lactate dehydrogenase that classically accompany pump thrombosis and that form the backbone of established diagnostic algorithms. What stood out instead was the device’s own telemetry: an abrupt decline in estimated pump flow recorded by the system monitor. In a device that continuously reports flow, power, pulsatility index, and speed, a sudden fall in flow is a mechanical statement that something is obstructing the blood’s path through the pump or its conduits.

The clinical team pursued the signal aggressively. Contrast-enhanced computed tomography was performed, and the imaging raised suspicion of thrombus formation within the outflow graft, the conduit that carries blood from the pump into the aorta. Faced with a plausible mechanical obstruction and a device already showing declining performance, the surgeons proceeded to an emergent pump exchange. The decision proved prescient. Subsequent analysis of the explanted device by the manufacturer demonstrated thrombus attached to the metallic edge at the inflow aspect of the pump, the region where blood enters from the left ventricle. Notably, no thrombus was identified on the rotor or on the impeller blade surfaces, indicating that the clot had lodged at the pump’s entry rather than accumulating on its moving parts.

This anatomical detail matters because it helps explain the paradoxical laboratory picture. Hemolysis, the destruction of red blood cells that releases free hemoglobin into plasma, is most severe when thrombus interacts directly with the rapidly spinning rotor. A thrombus sitting at the inflow edge, partially obstructing inflow rather than churning against the impeller, can reduce flow while generating comparatively little shear-related blood damage. The result is a thrombotic event that evades the standard biochemical radar. The authors argue that this case exposes the limitations of relying solely on laboratory findings for early detection and prediction of early HeartMate 3 pump thrombosis, and they emphasize that an abrupt decline in pump flow, even in the absence of marked hemolysis or increased pump power, may represent an early and clinically important warning indicator.

The diagnostic challenge in continuous-flow ventricular assist devices is well documented in the literature the authors cite. Algorithms developed more than a decade ago, including the widely used approach published by Goldstein and colleagues in 2013, built diagnosis around a constellation of findings: hemolysis, rising pump power, low flow, and echocardiographic abnormalities. Later work by Scandroglio and colleagues refined the evaluation of blood flow obstructions, and a systematic analysis by Kaufmann and colleagues in 2022 catalogued thrombus formation at the inflow cannula of continuous-flow devices. Yet the HeartMate 3’s hemocompatibility profile has shifted the epidemiology. Pump thrombosis is now so uncommon that individual cases carry outsized educational value, and each one refines the community’s understanding of how the complication can present.

Early postoperative thrombosis is a particularly treacherous subset. Reported cases include thrombosis within one hour of implantation, intraoperative pump thrombosis, and acute events in the first days after surgery, as documented by Shah and colleagues, Karuppiah and colleagues, and Bunge and colleagues in separate reports. The early period is a perfect storm of prothrombotic conditions: fresh surgical surfaces, inflammatory activation, altered anticoagulation management, and a healing heart adapting to unloading by the new device. A patient in this window who develops a flow abnormality may be dismissed as having volume shifts, arrhythmia, or right heart dysfunction, all of which can alter pump flow estimates. The Kurume case demonstrates why an abrupt change should instead prompt immediate structural evaluation rather than watchful waiting.

The technology itself deserves attention in understanding why flow telemetry is such a sensitive indicator. The HeartMate 3 operates at a fixed speed set by the clinician, typically around 5,000 to 6,000 revolutions per minute, and the controller estimates flow from the relationship between power consumption and speed. When inflow becomes obstructed, the pump essentially runs against a partial vacuum, and the estimated flow falls even though the impeller continues spinning at its commanded speed. Pump power, by contrast, may change little when the obstruction is at the inflow rather than within the rotor region, which is precisely the pattern observed here. The artificial pulse, a periodic speed modulation unique to the HeartMate 3 that washes all surfaces of the pump, also influences the flow waveform, and clinicians familiar with its normal pulsatility signature can detect deviations that suggest inflow problems. In this case, the flow decline was abrupt enough to stand out against the patient’s baseline, functioning as the device’s own distress signal.

Contrast-enhanced computed tomography emerged as the decisive diagnostic step, and its role in this case reinforces a growing consensus that imaging should be part of the early evaluation of suspected device obstruction. Echocardiography remains the first-line tool for assessing inflow cannula position, ventricular size, and valve function, but it can miss thrombus within the outflow graft or at the pump’s inflow edge. Computed tomography with contrast offers a direct view of the entire blood path from ventricle to aorta, and in this patient it converted an ambiguous telemetry finding into a surgical indication. The authors’ sequence, from flow alarm to laboratory review to cross-sectional imaging to emergent exchange, effectively models the pathway they believe should be followed when abrupt flow decline appears without an obvious hemodynamic explanation.

The broader message for the mechanical circulatory support community is one of vigilance and humility about traditional markers. The HeartMate 3 has transformed outcomes for patients with advanced heart failure, with five-year results from the MOMENTUM 3 trial showing superior survival and fewer adverse events than earlier devices. But hemocompatibility is not immunity, and the rare thrombosis that does occur may present in atypical ways. The Kurume team, supported in part by a Japan Society for the Promotion of Science KAKENHI grant, closes their report with a clear clinical directive: prompt recognition and intervention are essential to prevent clinical deterioration. For the thousands of clinicians who monitor HeartMate 3 patients through daily device downloads, the case reframes a familiar number on the screen. An abrupt fall in pump flow is not a curiosity to be observed; it is a call to action, potentially the first and only warning that a life-sustaining pump is beginning to clot from the inside.

Subject of Research: Early detection of HeartMate 3 pump thrombosis using abrupt pump flow decline as an initial warning indicator

Article Title: Abrupt flow decline as the initial indicator of early HeartMate 3 pump thrombosis

Article References: Ishii, Y., Kato, T. S., Takagi, K., Sano, S., Yoshimatsu, S., Shinoda, M., Yanai, T., Shibata, T., Uehara, M., Uchimura, H., Sugihara, G., Fukumoto, Y., & Tayama, E. (2026). Abrupt flow decline as the initial indicator of early HeartMate 3 pump thrombosis. Journal of Artificial Organs, 29(4), Article 61. https://doi.org/10.1007/s10047-026-01588-1

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01588-1

Keywords: HeartMate 3, pump thrombosis, LVAD, mechanical circulatory support, pump flow, hemolysis, outflow graft, computed tomography, heart failure, ventricular assist device, low flow alarm, device thrombosis